Skip to main content

Table 1 Ovarian weights in rats injected with a low, middle and a high dose of the Reference Standard, Bravelle®, Menopur®, or a mixture of Bravelle® and Menopur® reconstituted in 0.9% saline and mixed in the same syringe.

From: Mixed protocols: Multiple ratios of FSH and LH bioactivity using highly purified, human-derived FSH (BRAVELLE) and highly purified hMG (MENOPUR) are unaltered by mixing together in the same syringe

Hormone (FSH:LH)a

Total no. rats

Ovarian weights (mean ± SEM)b*

  

Lowc dose

Middled dose

Highe dose

Reference Standard

48

93.55 ± 4.17

151.37 ± 4.00

193.01 ± 5.02

Bravelle® (75:0)

48

92.31 ± 3.02

149.60 ± 3.29

201.37 ± 4.56

Menopur® (75:75)

48

92.19 ± 3.45

151.51 ± 2.62

194.92 ± 4.03

Bravelle® + Menopur®

(150:75)

48

97.29 ± 2.80

148.82 ± 3.65

199.59 ± 4.30

(300:75)

48

92.38 ± 3.37

157.08 ± 3.82

192.62 ± 5.50

(300:225)

48

95.75 ± 2.94

149.50 ± 6.11

195.39 ± 6.13

  1. * The magnitude of this increase was similar across treatment groups (treatment × dose P = 0.71)
  2. a Ratio of FSH:LH bioactivity expressed in IUs
  3. b Combined ovarian weights from the 2 replicates (replicate × treatment × dose)
  4. c Low dose = 1.9 IU FSH/0.6 mL
  5. d Middle dose = 3.8 IU FSH/0.6 mL
  6. e High dose = 7.6 IU FSH/0.6 mL